Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Muscle Invasive Bladder Urothelial Carcinoma: early-phase trial registry
4 of 5 indexed Non-Muscle Invasive Bladder Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Non-Muscle Invasive Bladder Urothelial Carcinoma: 5 US clinical trials tracked, 4 recruiting.
Non-Muscle Invasive Bladder Urothelial Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition non-muscle-invasive-bladder-urothelial-carcinoma
OPEN 4 | RECR 80% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Non-Muscle Invasive Bladder Urothelial Carcinoma lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Muscle Invasive Bladder Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Muscle Invasive Bladder Urothelial Carcinoma is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non-Muscle Invasive Bladder Urothelial Carcinoma research.
National Cancer Institute (NCI) accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Non-Muscle Invasive Bladder Urothelial Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 92 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Non-Muscle Invasive Bladder Urothelial Carcinoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
NCT06770582
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Fox Chase Cancer Center
NCT06396533
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
John Sfakianos
NCT06503614
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT05483868
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
NCT04164082
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Muscle Invasive Bladder Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Muscle Invasive Bladder Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Muscle Invasive Bladder Urothelial Carcinoma page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Non-Muscle Invasive Bladder Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Non-Muscle Invasive Bladder Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Muscle Invasive Bladder Urothelial Carcinoma condition card totals 5 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.